Roche chief Thomas Schinecker's 'Clone or die' T-shirt captured the urgency facing the Swiss pharmaceutical giant. After acquiring Genentech for $47bn in 2009, Roche built an oncology empire around Herceptin and Avastin, pioneering monoclonal antibodies when the field was unproven.

The company dominated cancer treatment for years, but rivals like Merck and AstraZeneca have surged ahead in immunotherapies and targeted treatments. Merck's Keytruda now leads as the world's best-selling cancer drug, while Roche's high-profile tiragolumab trial disappointed in 2022. Its obesity drug deal with Zealand Pharma for $5.3bn also showed weaker results than competitors.

Schinecker's 2023 reset narrowed research to five core areas and imposed stricter development hurdles. The pipeline's estimated value jumped 63% since 2022, with giredestrant emerging as a potential blockbuster for breast cancer prevention. Brain Shuttle technology targeting Alzheimer's represents another major wager.

Analysts see cautious optimism, with Citi noting the portfolio has 'turned a corner.' However, Jefferies warns excessive cost discipline risks killing innovation. The recovery remains a 'show me' story as investors await commercial proof of Roche's renewed pipeline strategy.